Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.55 |
| ▸ | MGLL | Q99685 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | FAAH | O00519 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | XBP1 | P17861 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9185109 | 1.00 | PTGS1 (0.55) | PTGS1PTGS2MGLLSMN1; SMN2ALDH1A1 | |
| SCHEMBL57249 | 1.00 | PTGS1 (0.55) | PTGS1PTGS2MGLLSMN1; SMN2ALDH1A1 | |
| SCHEMBL11033299 | 1.00 | PTGS1 (0.55) | PTGS1PTGS2MGLLSMN1; SMN2ALDH1A1 | |
| SCHEMBL946090 | 1.00 | PTGS1 (0.55) | PTGS1PTGS2MGLLSMN1; SMN2ALDH1A1 | |
| SCHEMBL18918259 | 0.98 | PTGS1 (0.53) | PTGS1PTGS2MGLLSMN1; SMN2ALDH1A1 | |
| SCHEMBL105903 | 0.94 | PTGS1 (0.46) | PTGS1PTGS2MGLLSMN1; SMN2ALDH1A1 | |
| SCHEMBL15578882 | 0.92 | PTGS1 (0.48) | PTGS1PTGS2MGLLSMN1; SMN2ALDH1A1 | |
| SCHEMBL15426046 | 0.91 | PTGS1 (0.49) | PTGS1PTGS2MGLLSMN1; SMN2ALDH1A1 | |
| SCHEMBL17193752 | 0.91 | PTGS1 (0.49) | PTGS1PTGS2MGLLSMN1; SMN2ALDH1A1 | |
| SCHEMBL12014013 | 0.91 | PTGS1 (0.46) | PTGS1PTGS2MGLLSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120060245-A | SiRNA antibody conjugate and application thereof | 佑嘉(杭州)生物医药科技有限公司 | 2025-05-30 | — | — | CN | claimed |
| WO-2023146293-A1 | IMMUNOCONJUGATE TARGETING C-KIT | 주식회사 노벨티노빌리티 | 2023-08-03 | — | — | WO | claimed |
| CN-110090635-B | GSH affinity chromatography medium for purifying GST-tag fusion protein, and preparation method and application thereof | 武汉菲恩生物科技有限公司 | 2021-11-16 | — | — | CN | claimed |
| WO-2020004535-A1 | SENSOR CHIP FOR HIGH-SENSITIVITY DETECTION OF CELLS, ETC. | 株式会社堀場製作所 | 2020-01-02 | — | — | WO | claimed |
| EP-2261666-B1 | METHOD FOR DETECTION OF PNEUMOCOCCUS | OTSUKA PHARMA CO LTD (JP) | 2015-12-02 | — | — | EP | claimed |
| EP-2903450-A1 | USE OF AN ION EXCHANGE MEMBRANE TO REMOVE IMPURITIES FROM CELL-BINDING AGENT CYTOTOXIC AGENT CONJUGATES | ImmunoGen, Inc. (US) | 2015-08-12 | — | — | EP | claimed |
| EP-2904089-A1 | USE OF A PVDF MEMBRANE TO PURIFY CELL-BINDING AGENT CYTOTOXIC AGENT CONJUGATES | ImmunoGen, Inc. (US) | 2015-08-12 | — | — | EP | claimed |
| EP-2790724-A1 | USE OF N-HYDROXYSUCCINIMIDE TO IMPROVE CONJUGATE STABILITY | ImmunoGen, Inc. (US) | 2014-10-22 | — | — | EP | claimed |
| WO-2014055893-A1 | USE OF AN ION EXCHANGE MEMBRANE TO REMOVE IMPURITIES FROM CELL-BINDING AGENT CYTOTOXIC AGENT CONJUGATES | IMMUNOGEN, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| WO-2014055877-A1 | USE OF A PVDF MEMBRANE TO PURIFY CELL-BINDING AGENT CYTOTOXIC AGENT CONJUGATES | IMMUNOGEN, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| WO-2014055842-A1 | PROCESS FOR PREPARING STABLE ANTIBODY MAYTANSINOID CONJUGATES | IMMUNOGEN, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| EP-2691117-A2 | PROCESS FOR MANUFACTURING CONJUGATES OF IMPROVED HOMOGENEITY | Immunogen, Inc. (US) | 2014-02-05 | — | — | EP | claimed |
| EP-2675481-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES AND METHODS OF PREPARATION | ImmunoGen, Inc. (US) | 2013-12-25 | — | — | EP | claimed |
| WO-2013090590-A1 | USE OF N-HYDROXYSUCCINIMIDE TO IMPROVE CONJUGATE STABILITY | IMMUNOGEN, INC. (US) | 2013-06-20 | — | — | WO | claimed |
| WO-2012135522-A2 | PROCESS FOR MANUFACTURING CONJUGATES OF IMPROVED HOMOGENEITY | IMMUNOGEN, INC. (US) | 2012-10-04 | — | — | WO | claimed |
| WO-2012112708-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES AND METHODS OF PREPARATION | IMMUNOGEN, INC. (US) | 2012-08-23 | — | — | WO | claimed |
| US-8241857-B2 | Method for detection of pneumococcus | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-14 | — | — | US | claimed |
| EP-1689846-A2 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES, AND METHODS OF MAKING SAID CONJUGATES | Immunogen, Inc. (US) | 2006-08-16 | — | — | EP | claimed |
| WO-2005037992-A2 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES, AND METHODS OF MAKING SAID CONJUGATES | IMMUNOGEN, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| EP-4461422-B1 | METHOD FOR PRODUCING A MICROMECHANICAL ULTRASOUND TRANSDUCER AND ULTRASOUND TRANSDUCER | UNIV CHEMNITZ TECH (DE) | 2026-02-18 | — | — | EP | disclosed |
| EP-4688871-A1 | SITE-SPEICFIC ORTHOGONAL BIOCONJUGATE MODALITY AND APPLICATION THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-12467103-B2 | Ligase fusion proteins and application thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2025-11-11 | — | — | US | disclosed |
| US-20250241872-A1 | AFFINITY MEDICANT CONJUGATE | Illudent, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250228923-A1 | COMBINED VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-07-17 | — | — | US | disclosed |
| EP-3467106-B1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-20250188135-A1 | A MULTIPLE ANTIGEN PRESENTING SYSTEM (MAPS)-BASED STAPHYLOCOCCUS AUREUS VACCINE COMPRISING B- AND T-CELL ANTIGENS, IMMUNOGENIC COMPOSITION, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-06-12 | — | — | US | disclosed |
| CN-120060245-A | SiRNA antibody conjugate and application thereof | 佑嘉(杭州)生物医药科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120053677-A | Preparation method and application of siRNA antibody conjugate | 佑嘉(杭州)生物医药科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2025090774-A1 | CHEMOTHERAPEUTIC COMPOUNDS AND METHODS OF USE | SEAGEN INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250127912-A1 | COMPOSITIONS FOR DELIVERY OF POLYNUCLEOTIDES | MIRECULE, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| CN-112313249-B | Anti-complement component antibodies and methods of use | 中外制药株式会社 | 2025-04-11 | — | — | CN | disclosed |
| CN-119789863-A | Modified CMV virus-like particles | 赛巴动物健康股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2025055900-A1 | ENGINEERED RED BLOOD CELL FOR SITE-DIRECTED CONJUGATION OF PROTEIN BY MEANS OF CHEMICAL SMALL MOLECULE LINKER | 西湖生物医药科技(上海)有限公司 | 2025-03-20 | — | — | WO | disclosed |
| US-12213929-B2 | Method, apparatus, and system for teleoperated, motorized rehabilitative cycling | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4257186-B1 | AFFINITY MEDICANT CONJUGATES | AF CHEMICALS LLC (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-3601329-B1 | GIP RECEPTOR ACTIVATING PEPTIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2024-12-04 | — | — | EP | disclosed |
| EP-4461422-A1 | METHOD FOR PRODUCING A MICROMECHANICAL ULTRASOUND TRANSDUCER AND ULTRASOUND TRANSDUCER | Technische Universität Chemnitz (DE) | 2024-11-13 | — | — | EP | disclosed |
| CN-112514320-B | Dynamic cryptography key expansion | 高通股份有限公司 | 2024-11-05 | — | — | CN | disclosed |
| US-12122815-B2 | GIP receptor agonist peptide compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-22 | — | — | US | disclosed |
| WO-2024199432-A1 | SITE-SPEICFIC ORTHOGONAL BIOCONJUGATE MODALITY AND APPLICATION THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2024-10-03 | — | — | WO | disclosed |
| US-12090198-B2 | Combined vaccine against mycobacterium tuberculosis | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2024-09-17 | — | — | US | disclosed |
| CN-111556895-B | Anti-C1S antibodies and methods of use | 中外制药株式会社 | 2024-09-13 | — | — | CN | disclosed |
| CN-113429559-B | Six-arm polyethylene glycol derivative with terminal iso-functionalization and preparation method thereof | 厦门赛诺邦格生物科技股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-112694608-B | Six-arm polyethylene glycol derivative, preparation method and modified biological related substance | 厦门赛诺邦格生物科技股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-108137681-B | Optimized variants of anti-VEGF antibodies | 豪夫迈·罗氏有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-115010915-B | Nitrogen-branched nine-arm polyethylene glycol derivative, preparation method and modified biologically-relevant substance thereof | 厦门赛诺邦格生物科技股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20240165192-A1 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2024-05-23 | — | — | US | disclosed |
| US-20240165251-A1 | IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES | SEAGEN INC (US) | 2024-05-23 | — | — | US | disclosed |
| US-20240156894-A1 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2024-05-16 | — | — | US | disclosed |
| US-20240139336-A1 | COMPLEXES FOR DELIVERY OF ANTIGENIC PEPTIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-02 | — | — | US | disclosed |
| US-20240123079-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | SEAGEN INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4347601-A1 | CAMPTOTHECIN ANALOGUES, CONJUGATES AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2024-04-10 | — | — | EP | disclosed |
| EP-4346906-A1 | ANTHRACYCLINE ANTIBODY CONJUGATES | Seagen Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2023169528-A9 | ENGINEERED RED BLOOD CELL TARGETING PD-1 | 西湖生物医药科技(上海)有限公司 | 2024-03-14 | — | — | WO | disclosed |
| US-11911435-B2 | Stable antibody-drug conjugate, preparation method therefor, and use thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| US-11911434-B2 | Stable antibody-drug conjugate, preparation method therefor, and use thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| WO-2024030577-A1 | IMMUNOSTIMULATORY ANTI-PD-L1-DRUG CONJUGATES | SEAGEN INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| CN-117279664-A | FOLR1 binding agents, conjugates thereof, and methods of use thereof | 普方生物制药美国公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-4288109-A1 | IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES | Seagen Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11834688-B2 | Ligase fusion proteins and application thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4277904-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | Seagen Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-112999362-B | Stable antibody drug coupling and preparation method and application thereof | 启德医药科技（苏州）有限公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023215740-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | SEAGEN INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| CN-109715206-B | Binding proteins and methods of use thereof | 恩格姆生物制药公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-116987187-A | Optimized variants of anti-VEGF antibodies | 豪夫迈·罗氏有限公司 | 2023-11-03 | — | — | CN | disclosed |
| WO-2023204329-A1 | NOVEL PEPTIDE-BASED CANCER IMMUNOTHERAPEUTIC AGENT | 트윈피그바이오랩(주) | 2023-10-26 | — | — | WO | disclosed |
| CN-116917484-A | Ligase fusion proteins and uses thereof | 启德医药科技（苏州）有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023195802-A1 | NOVEL-PEPTIDE-BASED ANTICANCER IMMUNOTHERAPEUTIC AGENT | 트윈피그바이오랩(주) | 2023-10-12 | — | — | WO | disclosed |
| EP-4257186-A2 | AFFINITY MEDICANT CONJUGATES | AF Chemicals LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| CN-116847887-A | Methods and compositions for treating autoimmune diseases and cancers | 伊诺西治疗公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2023178451-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2023-09-28 | — | — | WO | disclosed |
| CN-116751298-A | anti-ROR 2 antibodies, antibody fragments and their immunoconjugates and uses thereof | 生物蛋白有限公司 | 2023-09-15 | — | — | CN | disclosed |
| WO-2023169528-A1 | ENGINEERED RED BLOOD CELL TARGETING PD-1 | 西湖生物医药科技(上海)有限公司 | 2023-09-14 | — | — | WO | disclosed |
| CN-116731194-A | Lysozyme capable of penetrating cell membrane | 陈正贤 | 2023-09-12 | — | — | CN | disclosed |
| CN-108368510-B | Agonistic antibodies that specifically bind to human CD40 and methods of use | 詹森生物科技公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-3129357-B1 | AFFINITY MEDICANT CONJUGATES | AF CHEMICALS LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | IMMUNOGEN, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| CN-116635053-A | Methods of treating AXL-expressing cancers with anti-AXL antibodies, antibody fragments and immunoconjugates thereof | 生物蛋白有限公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2023146293-A1 | IMMUNOCONJUGATE TARGETING C-KIT | 주식회사 노벨티노빌리티 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023137158-A2 | T CELL MODULATORY POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-11701433-B2 | Complexes for delivery of antigenic peptides | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-07-18 | — | — | US | disclosed |
| CN-116375853-A | Anti-dengue virus antibodies, polypeptides containing variant FC regions, and methods of use | 中外制药株式会社 | 2023-07-04 | — | — | CN | disclosed |
| CN-114395051-B | Ligase fusion proteins and uses thereof | 启德医药科技（苏州）有限公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2023116993-A1 | AUTOMATED INTRALOGISTIC SYSTEM | symovo GmbH (DE) | 2023-06-29 | — | — | WO | disclosed |
| CN-116327926-A | Anti-dengue virus antibodies with cross-reactivity to Zika virus and methods of use | 中外制药株式会社 | 2023-06-27 | — | — | CN | disclosed |
| EP-4196590-A1 | LIGASE FUSION PROTEINS AND APPLICATIONS THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2023-06-21 | — | — | EP | disclosed |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| CN-116059344-A | Antibodies that specifically bind to PD-1 and uses thereof | 詹森生物科技公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116059346-A | Anti-myostatin antibodies and methods of use | 中外制药株式会社 | 2023-05-05 | — | — | CN | disclosed |
| CN-116072302-A | Medical unbalanced data classification method based on biased random forest model | 西安电子科技大学 | 2023-05-05 | — | — | CN | disclosed |
| WO-2023072349-A1 | DRIVERLESS TRANSPORT VEHICLE | symovo GmbH (DE) | 2023-05-04 | — | — | WO | disclosed |
| CN-115960223-A | anti-C5 antibodies and methods of use | 中外制药株式会社 | 2023-04-14 | — | — | CN | disclosed |
| WO-2023058705-A1 | DRUG FORMULATION OF ANTI-HLA-DQ2.5 ANTIBODY | 中外製薬株式会社 | 2023-04-13 | — | — | WO | disclosed |
| CN-115925922-A | Anti-C5 antibodies and methods of use | 中外制药株式会社 | 2023-04-07 | — | — | CN | disclosed |
| CN-115916812-A | GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2023-04-04 | — | — | CN | disclosed |
| US-20230097252-A1 | LIGASE FUSION PROTEINS AND APPLICATION THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-03-30 | — | — | US | disclosed |
| CN-115836122-A | T cell-based methods for predicting immunogenicity of polypeptides | 基因泰克公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11576876-B2 | Affinity Medicant Conjugate | AF CHEMICALS, LLC (US) | 2023-02-14 | — | — | US | disclosed |
| EP-4126921-A2 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-4126920-A2 | GIF RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-111869182-B | Method for authenticating equipment, communication system and communication equipment | 英国电讯有限公司 | 2023-01-17 | — | — | CN | disclosed |
| WO-2022270612-A1 | USE OF ANTI-CTLA-4 ANTIBODY | 中外製薬株式会社 | 2022-12-29 | — | — | WO | disclosed |
| US-20220403360-A1 | LIGASE FUSION PROTEINS AND APPLICATION THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| EP-4100216-A1 | OPERATING AN APPLICATION OF A ROBOT SYSTEM | KUKA Deutschland GmbH (DE) | 2022-12-14 | — | — | EP | disclosed |
| US-20220362367-A1 | MULTIPLE ANTIGEN PRESENTING SYSTEM (MAPS)-BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGENIC COMPOSITION, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-11-17 | — | — | US | disclosed |
| CN-115335395-A | QD administration of GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2022-11-11 | — | — | CN | disclosed |
| WO-2022220275-A1 | ANTI-C1s ANTIBODY | 中外製薬株式会社 | 2022-10-20 | — | — | WO | disclosed |
| CN-115124573-A | Novel cytotoxic molecules for use in cell binding molecule-drug conjugates | 杭州多禧生物科技有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-11453870-B2 | Ligase fusion proteins and application thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO. LTD. (CN) | 2022-09-27 | — | — | US | disclosed |
| CN-109311969-B | Anti-myostatin antibodies and methods of use | 中外制药株式会社 | 2022-09-27 | — | — | CN | disclosed |
| CN-108430509-B | Antibodies that specifically bind TIM-3 and uses thereof | 詹森生物科技公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-115052718-A | Application of operating robot system | 库卡德国有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-108780094-B | Diagnostic methods using conditionally active antibodies | 生物蛋白有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-115028721-A | Anti-myostatin antibodies, polypeptides comprising variant FC regions, and methods of use | 中外制药株式会社 | 2022-09-09 | — | — | CN | disclosed |
| CN-109312326-B | anti-C5 antibodies and methods of use | 中外制药株式会社 | 2022-09-09 | — | — | CN | disclosed |
| CN-115010915-A | Nitrogen branched nine-arm polyethylene glycol derivative, preparation method and biological related substance modified by nitrogen branched nine-arm polyethylene glycol derivative | 厦门赛诺邦格生物科技股份有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-108697791-B | Antibodies that specifically bind to PD-1 and uses thereof | 詹森生物科技公司 | 2022-08-23 | — | — | CN | disclosed |
| US-20220251530-A1 | LIGASE FUSION PROTEINS AND APPLICATION THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2022-08-11 | — | — | US | disclosed |
| WO-2022160156-A1 | LIGASE FUSION PROTEINS AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2022-08-04 | — | — | WO | disclosed |
| CN-110591079-B | Preparation method of monofunctional nonlinear polyethylene glycol | 厦门赛诺邦格生物科技股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-07-21 | — | — | US | disclosed |
| WO-2022155518-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | SEAGEN INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| CN-108473562-B | Anti-myostatin antibodies, polypeptides comprising variant FC regions, and methods of use | 中外制药株式会社 | 2022-06-17 | — | — | CN | disclosed |
| WO-2022115772-A1 | METHODS FOR USING NEUROTROPHIN RECEPTOR BINDING CONJUGATE COMPOSITIONS IN THE TREATMENT OF A NEUROLOGICAL CONDITION | MANZANITA PHARMACEUTICALS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| CN-114478790-A | Antibodies that specifically bind to PD-1 and TIM-3 and uses thereof | 詹森生物科技公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114478760-A | anti-C5 antibodies and methods of use | 中外制药株式会社 | 2022-05-13 | — | — | CN | disclosed |
| US-20220143208-A1 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | IMMUNOGEN, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-20220133649-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-05 | — | — | US | disclosed |
| CN-109477094-B | Peptide compounds | 武田药品工业株式会社 | 2022-04-26 | — | — | CN | disclosed |
| CN-114395051-A | Ligase fusion protein and application thereof | 启德医药科技（苏州）有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-107074879-B | Novel cytotoxic molecules for use in cell binding molecule-drug conjugates | 杭州多禧生物科技有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20220104989-A1 | METHOD, APPARATUS, AND SYSTEM FOR TELEOPERATED, MOTORIZED REHABILITATIVE CYCLING | NATIONAL SCIENCE FOUNDATION | 2022-04-07 | — | — | US | disclosed |
| CN-114206340-A | Methods of treating follicular lymphoma using anti-CD 79B immunoconjugates | 豪夫迈·罗氏有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-11241398-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2022-02-08 | — | — | US | disclosed |
| CN-110643032-B | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20220008467-A1 | T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof | CUE BIOPHARMA, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20210401924-A1 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-11-30 | — | — | US | disclosed |
| CN-110090635-B | GSH affinity chromatography medium for purifying GST-tag fusion protein, and preparation method and application thereof | 武汉菲恩生物科技有限公司 | 2021-11-16 | — | — | CN | disclosed |
| WO-2021195411-A1 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| CN-113429559-A | Six-arm polyethylene glycol derivative with end hetero-functionalized and preparation method thereof | 厦门赛诺邦格生物科技股份有限公司 | 2021-09-24 | — | — | CN | disclosed |
| US-11125742-B2 | Non-specific reaction inhibitor, method for inhibiting non-specific reaction, and kit | LSI MEDIENCE CORPORATION (JP) | 2021-09-21 | — | — | US | disclosed |
| US-11040084-B2 | Stable antibody-drug conjugate, preparation method therefor, and use thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2021-06-22 | — | — | US | disclosed |
| US-20210177929-A1 | NEW STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2021-06-17 | — | — | US | disclosed |
| EP-3814378-A1 | IMMUNOCONJUGATES TARGETING ADAM9 AND METHODS OF USE THEREOF | ImmunoGen, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-112694608-A | Six-arm polyethylene glycol derivative, preparation method and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2021-04-23 | — | — | CN | disclosed |
| EP-3765525-A1 | ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Zymeworks Inc. (CA) | 2021-01-20 | — | — | EP | disclosed |
| CN-108530617-B | Branched polyethylene glycol heterobifunctional derivative, preparation method thereof and two-component bio-related substance conjugate thereof | 厦门赛诺邦格生物科技股份有限公司 | 2020-11-27 | — | — | CN | disclosed |
| EP-3678691-A1 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | Cue Biopharma, Inc. (US) | 2020-07-15 | — | — | EP | disclosed |
| WO-2020132365-A2 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132366-A2 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-10660969-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2020-05-26 | — | — | US | disclosed |
| CN-110643032-A | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2020-01-03 | — | — | CN | disclosed |
| WO-2020004535-A1 | SENSOR CHIP FOR HIGH-SENSITIVITY DETECTION OF CELLS, ETC. | 株式会社堀場製作所 | 2020-01-02 | — | — | WO | disclosed |
| CN-110591079-A | Preparation method of monofunctional nonlinear polyethylene glycol | 厦门赛诺邦格生物科技股份有限公司 | 2019-12-20 | — | — | CN | disclosed |
| EP-3558391-A1 | IMMUNOCONJUGATES TARGETING ADAM9 AND METHODS OF USE THEREOF | Immunogen, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-10434182-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2019-10-08 | — | — | US | disclosed |
| US-20190285576-A1 | SEMICONDUCTOR SENSOR, METHOD FOR PRODUCING THE SAME, AND COMBINED SENSOR | TORAY INDUSTRIES, INC. (JP) | 2019-09-19 | — | — | US | disclosed |
| WO-2019173911-A1 | ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | ZYMEWORKS INC. (CA) | 2019-09-19 | — | — | WO | disclosed |
| EP-3130608-B1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-3531131-A1 | SEMICONDUCTOR SENSOR AND MANUFACTURING METHOD FOR SAME, AND COMPOUND SENSOR | Toray Industries, Inc. (JP) | 2019-08-28 | — | — | EP | disclosed |
| EP-3525824-A1 | LONG ACTING MULTI-SPECIFIC MOLECULES AND RELATED METHODS | Princeton Enduring Biotech, Inc. (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-3517114-A1 | NEW STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD AND USE THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2019-07-31 | — | — | EP | disclosed |
| EP-3138568-B1 | NEW STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2019-04-17 | — | — | EP | disclosed |
| WO-2019051091-A1 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| WO-2018160539-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
| US-20180214561-A1 | EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2018-08-02 | — | — | US | disclosed |
| WO-2018119196-A1 | IMMUNOCONJUGATES TARGETING ADAM9 AND METHODS OF USE THEREOF | IMMUNOGEN, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| EP-2728354-B1 | NON-SPECIFIC REACTION INHIBITOR, METHOD FOR INHIBITING NON-SPECIFIC REACTION, AND KIT | LSI MEDIENCE CORP (JP) | 2018-06-13 | — | — | EP | disclosed |
| EP-3315531-A1 | 8-ARM POLYETHYLENE GLYCOL DERIVATIVE, MANUFACTURING METHOD AND MODIFIED BIO-RELATED SUBSTANCE THEREBY | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2018-05-02 | — | — | EP | disclosed |
| WO-2018075308-A1 | LONG ACTING MULTI-SPECIFIC MOLECULES AND RELATED METHODS | PRINCETON ENDURING BIOTECH, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-3188733-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | ImmunoGen, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| US-20170112944-A1 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2017-04-27 | — | — | US | disclosed |
| EP-3138568-A1 | NEW STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2017-03-08 | — | — | EP | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| EP-3041952-A1 | COMPOSITIONS FOR RNA-CHROMATIN INTERACTION ANALYSIS AND USES THEREOF | The Jackson Laboratory (US) | 2016-07-13 | — | — | EP | disclosed |
| WO-2016036794-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
| EP-2261666-B1 | METHOD FOR DETECTION OF PNEUMOCOCCUS | OTSUKA PHARMA CO LTD (JP) | 2015-12-02 | — | — | EP | disclosed |
| US-9173961-B2 | CD20 antibodies and uses thereof | IMMUNOGEN, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150276740-A1 | METHOD FOR DETERMINING KINASE ACTIVITY | SYSMEX CORPORATION (JP) | 2015-10-01 | — | — | US | disclosed |
| WO-2015035108-A1 | COMPOSITIONS FOR RNA-CHROMATIN INTERACTION ANALYSIS AND USES THEREOF | THE JACKSON LABORATORY (US) | 2015-03-12 | — | — | WO | disclosed |
| US-8921124-B2 | Pyrazole-based cyanine dye | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| EP-2804631-A1 | SURROBODY COJUGATES | Sea Lane Biotechnologies,llc. (US) | 2014-11-26 | — | — | EP | disclosed |
| US-20140193842-A1 | NON-SPECIFIC REACTION INHIBITOR, METHOD FOR INHIBITING NON-SPECIFIC REACTION, AND KIT | MITSUBISHI CHEMICAL MEDIENCE CORPORATION (JP) | 2014-07-10 | — | — | US | disclosed |
| EP-2728354-A1 | NON-SPECIFIC REACTION INHIBITOR, AND METHOD AND KIT FOR INHIBITING NON-SPECIFIC REACTION | Mitsubishi Chemical Medience Corporation (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-8709432-B2 | Methods for increasing efficacy of FOLR1 cancer therapy | IMMUNOGEN, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2691117-A2 | PROCESS FOR MANUFACTURING CONJUGATES OF IMPROVED HOMOGENEITY | Immunogen, Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| EP-2675480-A1 | METHODS OF PREPARATION OF CONJUGATES | ImmunoGen, Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2675481-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES AND METHODS OF PREPARATION | ImmunoGen, Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| WO-2013109994-A1 | SURROBODY COJUGATES | SEA LANE BIOTECHNOLOGIES, LLC (US) | 2013-07-25 | — | — | WO | disclosed |
| WO-2013088141-A1 | POLYPEPTIDE COMPRISING THE SEQUENCE EGPWLEEEEEAYG LINKED TO AN IMMUNOGENIC CARRIER | ASTRIMMUNE LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| EP-2533810-A1 | CD20 ANTIBODIES AND USES THEREOF | ImmunoGen, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120282175-A1 | Methods for Increasing Efficacy of FOLR1 Cancer Therapy | IMMUNOGEN, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| WO-2012135522-A2 | PROCESS FOR MANUFACTURING CONJUGATES OF IMPROVED HOMOGENEITY | IMMUNOGEN, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012112687-A1 | METHODS OF PREPARATION OF CONJUGATES | IMMUNOGEN, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012112708-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES AND METHODS OF PREPARATION | IMMUNOGEN, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| EP-2486023-A1 | POTENT CONJUGATES AND HYDROPHILIC LINKERS | ImmunoGen, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2012033298-A3 | METHOD FOR MANUFACTURING A NOX GAS SENSOR, AND NOX GAS SENSOR MANUFACTURED USING SAME | 일진머티리얼즈 주식회사 (KR) | 2012-05-10 | — | — | WO | disclosed |
| EP-2006289-B1 | PYRAZOLE-TYPE CYANINE DYE | WAKO PURE CHEM IND LTD (JP) | 2011-11-30 | — | — | EP | disclosed |
| WO-2011100403-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN, INC (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011100398-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN, INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110195021-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110077204-A1 | Agent for Targeted Drug Delivery To Cerebral Neurons | KAGOSHIMA UNIVERSITY (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20110020848-A1 | METHOD FOR DETECTION OF PNEUMOCOCCUS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-2261666-A1 | METHOD FOR DETECTION OF PNEUMOCOCCUS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
| WO-2010126551-A1 | POTENT CONJUGATES AND HYDROPHILIC LINKERS | IMMUNOGEN, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100173287-A1 | METHOD OF ANALYZING NUCLEIC ACID | HITACHI, LTD. (JP) | 2010-07-08 | — | — | US | disclosed |
| US-20100151490-A1 | Antigenic Protein Conjugates and Process for Preparing Same | ABBOTT LABORATORIES (US) | 2010-06-17 | — | — | US | disclosed |
| US-20090298717-A1 | MICRO-PARTICLE ARRAY ANALYSIS SYSTEM, MICRO-PARTICLE ARRAY KIT, AND CHEMICAL ANALYSIS METHOD | KOHARA YOSHINOBU | 2009-12-03 | — | — | US | disclosed |
| WO-2009134952-A2 | POTENT CONJUGATES AND HYDROPHILIC LINKERS | IMMUNOGEN, INC (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090220607-A1 | POLYMERIC COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH | 2009-09-03 | — | — | US | disclosed |
| EP-2063913-A2 | ANTIGENIC PROTEIN CONJUGATES AND PROCESS FOR PREPARING SAME | Abbott Laboratories (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090069546-A1 | PYRAZOLE-BASED CYANINE DYE | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-2006289-A1 | PYRAZOLE-TYPE CYANINE DYE | Wako Pure Chemical Industries, Ltd. (JP) | 2008-12-24 | — | — | EP | disclosed |
| EP-1985311-A1 | AGENT FOR TARGETING DRUG TO CEREBRAL NEURON | Kagoshima University (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-20080220448-A1 | ANTIGENIC PROTEIN CONJUGATES AND PROCESS FOR PREPARING SAME | ABBOTT LABORATORIES | 2008-09-11 | — | — | US | disclosed |
| EP-1934265-A2 | POLYMERIC COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | University of Utah Research Foundation (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1917030-A2 | IMMUNOCONJUGATE FORMULATIONS | Immunogen, Inc. (US) | 2008-05-07 | — | — | EP | disclosed |
| WO-2008027944-A2 | ANTIGENIC PROTEIN CONJUGATES AND PROCESS FOR PREPARING SAME | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007035296-A2 | POLYMERIC COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007019232-A2 | IMMUNOCONJUGATE FORMULATIONS | IMMUNOGEN, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070004027-A1 | Method for manufacturing a biosensor element | HITACHI SOFTWARE ENGINEERING CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1726661-A1 | Method for manufacturing a biosensor element | Hitachi Software Engineering Co., Ltd. (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-6921638-B2 | Hydrogel-based microarray signal amplification methods and devices therefor | AMERSHAM BIOSCIENCES AB (SE) | 2005-07-26 | — | — | US | disclosed |
| EP-1517910-A1 | PHOSPHORAMIDITES FOR COUPLING OLIGONUCLEOTIDES TO (2 + 2) PHOTOREACTIVE GROUPS | Amersham Biosciences AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| US-20040229346-A1 | Micro-particle array analysis system, micro-particle array kit, and chemical analysis method | HITACHI, LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1190254-B1 | ATTACHMENT OF BIOMOLECULE TO A POLYMERIC SOLID SUPPORT BY CYCLOADDITION OF A LINKER | AMERSHAM BIOSCIENCES AB (SE) | 2004-09-15 | — | — | EP | disclosed |
| US-6686161-B2 | CROSSLINKING OF THE HYDROGEL AND ATTACHMENT OF BIOMOLECULES CAN BE DONE IN A SINGLE STEP | AMERSHAM BIOSCIENCES AB (SE) | 2004-02-03 | — | — | US | disclosed |
| WO-2004002995-A1 | PHOSPHORAMIDITES FOR COUPLING OLIGONUCLEOTIDES TO [2 + 2] PHOTOREACTIVE GROUPS | AMERSHAM BIOSCIENCES AB (SE) | 2004-01-08 | — | — | WO | disclosed |
| US-6664061-B2 | Use and evaluation of a [2+2] photoaddition in immobilization of oligonucleotides on a three-dimensional hydrogel matrix | AMERSHAM BIOSCIENCES AB (SE) | 2003-12-16 | — | — | US | disclosed |
| US-20030124525-A1 | Use and evaluation of a [2+2] photocycloaddition in immobilization of oligonucleotides on a three-dimensional hydrogel matrix | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2003-07-03 | — | — | US | disclosed |
| US-20030096265-A1 | Phosphoramidites for coupling oligonucleotides to [2 + 2] photoreactive groups | MOTOROLA, INC. | 2003-05-22 | — | — | US | disclosed |
| US-20030078314-A1 | Methods and compositions for attachment of biomolecules to solid supports, hydrogels, and hydrogel arrays | MOTOROLA INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2003014392-A2 | USE AND EVALUATION OF A [2+2] PHOTOADDITION IN IMMOBILIZATION OF OLIGONUCLEOTIDES ON A THREE-DIMENSIONAL HYDROGEL MATRIX | AMERSHAM BIOSCIENCES AB (SE) | 2003-02-20 | — | — | WO | disclosed |
| US-20020146730-A1 | Hydrogel-based microarray signal amplification methods and devices therefor | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2002-10-10 | — | — | US | disclosed |
| US-20020115740-A1 | Hydrogels and hydrogel arrays made from reactive prepolymers crosslinked by [2 + 2] cycloaddition | MOTOROLA, INC. | 2002-08-22 | — | — | US | disclosed |
| US-6372813-B1 | CROSSLINKING POLYACRYLAMIDE HYDROGEL, JOINING BIOMOLECULES ON SUPPORTS | MOTOROLA | 2002-04-16 | — | — | US | disclosed |
| US-5790627-A | Method and apparatus for observing a specimen using an X-ray microscope | RESEARCH DEVELOPMENT CORP. (JP) | 1998-08-04 | — | — | US | disclosed |
| US-5790627-A | Method and apparatus for observing a specimen using an X-ray microscope | RESEARCH DEVELOPMENT CORP. (JP) | 1998-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (42 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | PTGS1 2728/4885PTGS2 3312/4885MGLL 1795/4885 |
| US-10434182-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | MRPL38, ALG8, MRPS18A | PTGS1 1147/4885PTGS2 3073/4885MGLL 651/4885 |
| US-11040084-B2 | Stable antibody-drug conjugate, preparation method therefor, and use thereof | FCGR1A, FCGRT, FCGR2A | PTGS1 3657/4885PTGS2 4264/4885MGLL 1928/4885 |
| US-20240123079-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | CD47, CD22, FCGR2A | PTGS1 2352/4885PTGS2 2223/4885MGLL 1898/4885 |
| US-10660969-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | MRPL38, ALG8, COG8 | PTGS1 888/4885PTGS2 2689/4885MGLL 539/4885 |
| US-11701433-B2 | Complexes for delivery of antigenic peptides | IFNG, ALB, IFNAR1 | PTGS1 4364/4885PTGS2 4666/4885MGLL 4099/4885 |
| US-20090069546-A1 | PYRAZOLE-BASED CYANINE DYE | CBR3, CYB5R3, TST | PTGS1 3793/4885PTGS2 3252/4885MGLL 4698/4885 |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | PTGS1 2438/4885PTGS2 2811/4885MGLL 1320/4885 |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | ERBB2, EGFR, LANCL2 | PTGS1 2252/4885PTGS2 1946/4885MGLL 210/4885 |
| US-20090220607-A1 | POLYMERIC COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | PCBP1, PARG, ALG1 | PTGS1 1097/4885PTGS2 1405/4885MGLL 515/4885 |
| US-20240165192-A1 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | FCGR1A, FCGRT, FCGR2A | PTGS1 3657/4885PTGS2 4264/4885MGLL 1928/4885 |
| US-20240165251-A1 | IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES | CD47, FCGR2A, ICOS | PTGS1 1933/4885PTGS2 1584/4885MGLL 1721/4885 |
| US-11125742-B2 | Non-specific reaction inhibitor, method for inhibiting non-specific reaction, and kit | KIT, SPR, SHBG | PTGS1 469/4885PTGS2 692/4885MGLL 2928/4885 |
| US-20180214561-A1 | EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF | MRPL38, CXCL8, ALG8 | PTGS1 1042/4885PTGS2 2558/4885MGLL 1246/4885 |
| US-11911435-B2 | Stable antibody-drug conjugate, preparation method therefor, and use thereof | CYP4F11, FCGR1A, CD81 | PTGS1 3186/4885PTGS2 4045/4885MGLL 1323/4885 |
| US-20220362367-A1 | MULTIPLE ANTIGEN PRESENTING SYSTEM (MAPS)-BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGENIC COMPOSITION, AND USES THEREOF | CD14, TLR8, SPAG5 | PTGS1 4287/4885PTGS2 4202/4885MGLL 3395/4885 |
| US-20230097252-A1 | LIGASE FUSION PROTEINS AND APPLICATION THEREOF | LIG1, LIG3, STUB1 | PTGS1 4352/4885PTGS2 4409/4885MGLL 1649/4885 |
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | PCNA, EPCAM, MKI67 | PTGS1 3220/4885PTGS2 3095/4885MGLL 4831/4885 |
| US-20240156894-A1 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | FCGR1A, FCGRT, FCGR2A | PTGS1 3657/4885PTGS2 4264/4885MGLL 1928/4885 |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | PTGS1 2728/4885PTGS2 3312/4885MGLL 1795/4885 |
| US-12467103-B2 | Ligase fusion proteins and application thereof | LIG1, LIG3, STUB1 | PTGS1 4352/4885PTGS2 4409/4885MGLL 1649/4885 |
| US-20030096265-A1 | Phosphoramidites for coupling oligonucleotides to [2 + 2] photoreactive groups | PCNA, POLL, LIG4 | PTGS1 3658/4885PTGS2 2154/4885MGLL 4665/4885 |
| US-20220133649-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | PTGS1 2728/4885PTGS2 3312/4885MGLL 1795/4885 |
| US-20110195021-A1 | CD20 ANTIBODIES AND USES THEREOF | BCL9, BCL9L, BCL6B | PTGS1 4032/4885PTGS2 4326/4885MGLL 3121/4885 |
| US-20170112944-A1 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | FCGR1A, FCGRT, FCGR2A | PTGS1 3657/4885PTGS2 4264/4885MGLL 1928/4885 |
| US-20210401924-A1 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | FCGR1A, FCGRT, FCGR2A | PTGS1 3657/4885PTGS2 4264/4885MGLL 1928/4885 |
| US-20240139336-A1 | COMPLEXES FOR DELIVERY OF ANTIGENIC PEPTIDES | IFNG, ALB, IFNAR1 | PTGS1 4360/4885PTGS2 4673/4885MGLL 4099/4885 |
| US-20220251530-A1 | LIGASE FUSION PROTEINS AND APPLICATION THEREOF | LIG1, LIG3, STUB1 | PTGS1 4352/4885PTGS2 4409/4885MGLL 1649/4885 |
| US-20210177929-A1 | NEW STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | FCGR1A, CD81, FAR1 | PTGS1 3492/4885PTGS2 4321/4885MGLL 1927/4885 |
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | PTGS1 3090/4885PTGS2 3781/4885MGLL 1468/4885 |
| US-11911434-B2 | Stable antibody-drug conjugate, preparation method therefor, and use thereof | FCGR1A, FCGRT, FCGR2A | PTGS1 3657/4885PTGS2 4264/4885MGLL 1928/4885 |
| US-20080220448-A1 | ANTIGENIC PROTEIN CONJUGATES AND PROCESS FOR PREPARING SAME | PTMS, SPR, DNPEP | PTGS1 1712/4885PTGS2 2033/4885MGLL 3669/4885 |
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | ERBB2, EGFR, LANCL2 | PTGS1 2252/4885PTGS2 1946/4885MGLL 210/4885 |
| US-20220403360-A1 | LIGASE FUSION PROTEINS AND APPLICATION THEREOF | LIG1, LIG3, STUB1 | PTGS1 4352/4885PTGS2 4409/4885MGLL 1649/4885 |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, VIPR1 | PTGS1 686/4885PTGS2 1342/4885MGLL 2407/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | PTGS1 344/4885PTGS2 1230/4885MGLL 1181/4885 |
| US-11834688-B2 | Ligase fusion proteins and application thereof | LIG1, LIG3, STUB1 | PTGS1 4352/4885PTGS2 4409/4885MGLL 1649/4885 |
| US-11576876-B2 | Affinity Medicant Conjugate | FCER2, HDGF, FCGR2A | PTGS1 2728/4885PTGS2 3312/4885MGLL 1795/4885 |
| US-20100151490-A1 | Antigenic Protein Conjugates and Process for Preparing Same | PTMS, SPR, DNPEP | PTGS1 1712/4885PTGS2 2033/4885MGLL 3669/4885 |
| US-12122815-B2 | GIP receptor agonist peptide compounds and uses thereof | GIPR, GLP1R, GPR119 | PTGS1 1157/4885PTGS2 2039/4885MGLL 2318/4885 |
| US-11453870-B2 | Ligase fusion proteins and application thereof | LIG1, LIG3, STUB1 | PTGS1 4352/4885PTGS2 4409/4885MGLL 1649/4885 |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | HDGF, F11, F12 | PTGS1 344/4885PTGS2 1230/4885MGLL 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.